Jump to content

New Treatment for Cushing's?

Recommended Posts



Samaritan Pharma Aims At SP-6300 as New Innovative Treatment for Cushing's Syndrome



Files New Patent Application for SP-6300 Making Use

of SP-01A's Phase II Study Data


Drug SP-01A (HIV), SP-6300 (Cushing's) Demonstrates a Statistically

Significant Ability to Normalize High Cortisol in Humans


High Cortisol Cushing's is Caused by a Long-Term Use of

Corticosteroid Medications (Normally Administered to Lupus, Asthma,

and Rheumatoid Arthritis Patients)


LAS VEGAS, Feb. 6, 2007 (PRIME NEWSWIRE) (PRIMEZONE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, announced today its drug candidate SP-6300 has shown the ability to modulate excessive cortisol levels by lowering the hormone-stimulated corticosteroid formation in adrenal cells, and as a result could be a potentially new treatment for Cushing's Syndrome.



Cushing's Syndrome is a disorder of the adrenal glands leading to excess cortisol secretion. This means that there is too much cortisol hormone in the blood. Cushing's Syndrome is a hormonal disorder caused by prolonged exposure of the body's tissues to high levels of the hormone cortisol. It is sometimes called "hypercortisolism," and an estimated 10 to 15 of every million people are affected each year.


Long-term (chronic) use of corticosteroid medications, for the treatment of conditions such as lupus, asthma, and rheumatoid arthritis, is the most common cause of Cushing's Syndrome. Patients who develop Cushing's exhibit a variety of symptoms including weight gain, fatigue, muscle weakness, diabetes, high blood pressure, depression, and osteoporosis. If left untreated, Cushing's Syndrome can lead to death.


Dr. Greeson, CEO of Samaritan Pharmaceuticals stated, "There is an urgent need to develop new therapeutic agents, with a new and different mechanism of action, for Cushing's. It is commonly held that the cause of Cushing's is related to patients taking too much corticosteroid medications. We believe the addition of SP-6300 to normally prescribed medications might allow doctors to prescribe smaller doses of corticosteroid medications; to possibly decrease corticosteroid side effects, and increase their efficacy, at the same time."


Samaritan Pharmaceuticals: "We LIV... to Save Lives."


Samaritan is a small-cap Biotech, driven to discover, develop and commercialize innovative therapeutics' for AIDS, Alzheimer's, Cancer and Heart disease patients. Look at www.samaritanpharma.com. Please register on Website so we can notify you of upcoming conference calls, news and events.


Click here: Samaritan Pharmaceuticals -- Samaritan Technology Videos (http://www.samaritanpharma.com/html/videos.html)


The Samaritan Pharmaceuticals Inc. logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2670




The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K/A filed November 2, 2006. The company undertakes no duty to update forward-looking statements.


CONTACT: Samaritan Pharmaceuticals, Inc.

Richard Brown

(702) 735-7001


Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...